Dry Powder Inhaler Design and Particle Technology in Enhancing Pulmonary Drug Deposition: Challenges and Future Strategies

Overview

Journal Daru

Specialty Pharmacology

Date 2024 Jun 11

PMID 38861247

Authors

Nazrul Islam

Tan Suwandecha

Teerapol Srichana

Affiliations

Soon will be listed here.

Abstract

Objectives: The efficient delivery of drugs from dry powder inhaler (DPI) formulations is associated with the complex interaction between the device design, drug formulations, and patient's inspiratory forces. Several challenges such as limited emitted dose of drugs from the formulation, low and variable deposition of drugs into the deep lungs, are to be resolved for obtaining the efficiency in drug delivery from DPI formulations. The objective of this study is to review the current challenges of inhaled drug delivery technology and find a way to enhance the efficiency of drug delivery from DPIs.

Methods/evidence Acquisition: Using appropriate keywords and phrases as search terms, evidence was collected from the published articles following SciFinder, Web of Science, PubMed and Google Scholar databases.

Results: Successful lung drug delivery from DPIs is very challenging due to the complex anatomy of the lungs and requires an integrated strategy for particle technology, formulation design, device design, and patient inhalation force. New DPIs are still being developed with limited performance and future device design employs computer simulation and engineering technology to overcome the ongoing challenges. Many issues of drug formulation challenges and particle technology are concerning factors associated with drug dispersion from the DPIs into deep lungs.

Conclusion: This review article addressed the appropriate design of DPI devices and drug formulations aligned with the patient's inhalation maneuver for efficient delivery of drugs from DPI formulations.

Citing Articles

Development and Characterization of Spray-Dried Combined Levofloxacin-Ambroxol Dry Powder Inhaler Formulation.

Suraweera R, Spann K, Izake E, Wells T, Wang X, Islam N Pharmaceutics. 2025; 16(12.

PMID: 39771486 PMC: 11728515. DOI: 10.3390/pharmaceutics16121506.

Comprehensive In Vitro and In Silico Aerodynamic Analysis of High-Dose Ibuprofen- and Mannitol-Containing Dry Powder Inhalers for the Treatment of Cystic Fibrosis.

Party P, Piszman Z, Farkas A, Ambrus R Pharmaceutics. 2024; 16(11).

PMID: 39598588 PMC: 11597309. DOI: 10.3390/pharmaceutics16111465.

References

Chrystyn H, Saralaya D, Shenoy A, Toor S, Kastango K, Calderon E . Investigating the Accuracy of the Digihaler, a New Electronic Multidose Dry-Powder Inhaler, in Measuring Inhalation Parameters. J Aerosol Med Pulm Drug Deliv. 2021; 35(3):166-177. PMC: 9242715. DOI: 10.1089/jamp.2021.0031. View

Ding L, Brunaugh A, Thakkar R, Lee C, Zhao Q, Kalafat J . Comparison of HPMC Inhalation-Grade Capsules and Their Effect on Aerosol Performance Using Budesonide and Rifampicin DPI Formulations. AAPS PharmSciTech. 2022; 23(1):52. PMC: 8752038. DOI: 10.1208/s12249-021-02175-8. View

Gaikwad S, Pathare S, More M, Waykhinde N, Laddha U, Salunkhe K . Dry Powder Inhaler with the technical and practical obstacles, and forthcoming platform strategies. J Control Release. 2023; 355:292-311. DOI: 10.1016/j.jconrel.2023.01.083. View

Chvatal A, Ambrus R, Party P, Katona G, Jojart-Laczkovich O, Szabo-Revesz P . Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery. Int J Pharm. 2019; 559:68-75. DOI: 10.1016/j.ijpharm.2019.01.034. View

Rospond B, Krakowska A, Muszynska B, Opoka W . The history, current state and perspectives of aerosol therapy. Acta Pharm. 2023; 72(2):225-243. DOI: 10.2478/acph-2022-0017. View

Dhanda D, Tyagi P, Mirvish S, Kompella U . Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J Control Release. 2013; 168(3):239-50. DOI: 10.1016/j.jconrel.2013.03.027. View

Xiroudaki S, Schoubben A, Giovagnoli S, Rekkas D . Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives. Pharmaceutics. 2021; 13(9). PMC: 8467565. DOI: 10.3390/pharmaceutics13091455. View

Telko M, Hickey A . Dry powder inhaler formulation. Respir Care. 2005; 50(9):1209-27. View

Weers J, Son Y, Glusker M, Haynes A, Huang D, Kadrichu N . Idealhalers Versus Realhalers: Is It Possible to Bypass Deposition in the Upper Respiratory Tract?. J Aerosol Med Pulm Drug Deliv. 2018; 32(2):55-69. DOI: 10.1089/jamp.2018.1497. View

10.

Benque B, Khinast J . Carrier particle emission and dispersion in transient CFD-DEM simulations of a capsule-based DPI. Eur J Pharm Sci. 2021; 168:106073. DOI: 10.1016/j.ejps.2021.106073. View

11.

Yaqoubi S, Adibkia K, Nokhodchi A, Emami S, Alizadeh A, Hamishehkar H . Co-electrospraying technology as a novel approach for dry powder inhalation formulation of montelukast and budesonide for pulmonary co-delivery. Int J Pharm. 2020; 591:119970. DOI: 10.1016/j.ijpharm.2020.119970. View

12.

Sharif S, Muneer S, Wang T, Izake E, Islam N . Robust Wet Milling Technique for Producing Micronized Ibuprofen Particles with Improved Solubility and Dissolution. AAPS PharmSciTech. 2022; 24(1):16. DOI: 10.1208/s12249-022-02480-w. View

13.

Shetty N, Cipolla D, Park H, Zhou Q . Physical stability of dry powder inhaler formulations. Expert Opin Drug Deliv. 2019; 17(1):77-96. PMC: 6981243. DOI: 10.1080/17425247.2020.1702643. View

14.

Mitani R, Ohsaki S, Nakamura H, Watano S . Numerical Study on Particle Adhesion in Dry Powder Inhaler Device. Chem Pharm Bull (Tokyo). 2020; 68(8):726-736. DOI: 10.1248/cpb.c20-00106. View

15.

Haidl P, Heindl S, Siemon K, Bernacka M, Cloes R . Inhalation device requirements for patients' inhalation maneuvers. Respir Med. 2016; 118:65-75. DOI: 10.1016/j.rmed.2016.07.013. View

16.

Ali A, Abo Dena A, Yacoub M, El-Sherbiny I . Exploring the influence of particle shape and air velocity on the flowability in the respiratory tract: a computational fluid dynamics approach. Drug Dev Ind Pharm. 2019; 45(7):1149-1156. DOI: 10.1080/03639045.2019.1600534. View

17.

Hebbink G, Jaspers M, Peters H, Dickhoff B . Recent developments in lactose blend formulations for carrier-based dry powder inhalation. Adv Drug Deliv Rev. 2022; 189:114527. DOI: 10.1016/j.addr.2022.114527. View

18.

de Boer A, Hagedoorn P, Gjaltema D, Goede J, Frijlink H . Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler. Int J Pharm. 2006; 310(1-2):72-80. DOI: 10.1016/j.ijpharm.2005.11.030. View

19.

Chaurasiya B, Huang L, Du Y, Tang B, Qiu Z, Zhou L . Size-based anti-tumoral effect of paclitaxel loaded albumin microparticle dry powders for inhalation to treat metastatic lung cancer in a mouse model. Int J Pharm. 2018; 542(1-2):90-99. DOI: 10.1016/j.ijpharm.2018.02.042. View

20.

Vazda A, Xia W, Engqvist H . The use of heat to deliver fentanyl via pulmonary drug delivery. Int J Pharm X. 2021; 3:100096. PMC: 8521112. DOI: 10.1016/j.ijpx.2021.100096. View